A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (NCT06824467)
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)
🩺 Plain-English Summary (8th-Grade Level)
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham ( Site 0006) — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (195 Sites)
Showing the first 25 of 195 sites.
- University of Alabama at Birmingham ( Site 0006) — Birmingham, Alabama
- Alaska Women's Cancer Care ( Site 0096) — Anchorage, Alaska
- UCSF Medical Center at Mission Bay ( Site 0013) — San Francisco, California
- John Muir Health Cancer Center ( Site 0016) — Walnut Creek, California
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001) — New Haven, Connecticut
- Mount Sinai Braman Comprehensive Cancer Center ( Site 0078) — Miami Beach, Florida
- Sarasota Memorial Hospital ( Site 0075) — Sarasota, Florida
- Florida Cancer Specialists East ( Site 7000) — West Palm Beach, Florida
- Winship Cancer Institute of Emory University ( Site 0086) — Atlanta, Georgia
- Augusta University - Georgia Cancer Center ( Site 0066) — Augusta, Georgia
- Parkview Research Center at Parkview Regional Medical Center ( Site 0003) — Fort Wayne, Indiana
- Women's Cancer Care ( Site 0067) — Covington, Louisiana
- Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0008) — Scarborough, Maine
- Minnesota Oncology Hematology (MNO) ( Site 8002) — Maplewood, Minnesota
- St. Dominic's Hospital ( Site 0064) — Jackson, Mississippi
- Washington University School of Medicine ( Site 0052) — St Louis, Missouri
- Nebraska Methodist Hospital ( Site 0053) — Omaha, Nebraska
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0081) — Hackensack, New Jersey
- Rutgers Cancer Institute of New Jersey ( Site 0071) — New Brunswick, New Jersey
- University of New Mexico Comprehensive Cancer Center ( Site 0055) — Albuquerque, New Mexico
- NYU Langone Hospital - Long Island ( Site 0015) — Mineola, New York
- Laura and Isaac Perlmutter Cancer Center ( Site 0076) — New York, New York
- FirstHealth Cancer Center ( Site 0079) — Pinehurst, North Carolina
- University of Cincinnati Medical Center ( Site 0090) — Cincinnati, Ohio
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054) — Columbus, Ohio
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.